Advancing merkel cell carcinoma research: Diagnosis, immune checkpoint therapy, and future oncological perspectives explored

Merkel cell carcinoma is an uncommon but very aggressive cutaneous neuroendocrine cancer that primarily affects the elderly. It mainly affects sun-exposed regions and has been connected to two distinct carcinogenic pathways: Merkel cell polyomavirus integration and mutations brought on by UV exposure. Compared to such a low baseline, the incidence of Merkel cell carcinoma has increased dramatically over the previous few decades. The increase is probably due to improved diagnostic abilities and more attention rather than changed sickness patterns. This condition advances rapidly, making diagnosis and treatment challenging due to its high tendency for metastasis. The fundamentals of Merkel cell carcinoma, including its physiology and pathophysiology, diagnostic challenges, and the most current developments in therapeutic approaches, will be covered in this review, emphasizing the function of immune checkpoint inhibitors. The foundation of this review is an analysis of the body of existing research on Merkel cell carcinoma, focusing on papers released in the previous ten years, from 2008 to 2023. The sources include relevant peer-reviewed publications on the molecular processes of oncogenesis, clinical and pathological characteristics, and therapeutic developments about Merkel cell carcinoma. Merkel cell cancer serves as an example of how viral and UV-driven carcinogenesis naturally interact. Due to the biology of the tumor, only individuals who are positive for Merkel cell polyomavirus have a comparatively better prognosis than their counterparts who are exposed to UV radiation. Like programmed death-1 receptor inhibitors, immune checkpoint inhibitors offer a paradigm for treating Merkel cell cancer, with significant survival improvements even at an advanced stage. Therefore, future research will focus on clarifying resistance mechanisms to improve outcomes.